KYNTRA BIO INC.
KYNTRA BIO INC. (KYNB): 176 pipeline candidates · 18 upcoming catalysts · ~19 mo cash runway · 131 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
19.2 months
D/E -2.71 · 0% dilution
Lead: Phase 3
176 candidates
18 upcoming, next in ~12d
1 buy · 0 sells (180d)
A transparent, data-derived signal for KYNTRA BIO INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$28.3M
Cash
$37.0M
Quarterly Burn
$13.9M
Runway
19.2 mo
Revenue
$3.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (176 candidates)
| Drug | Phase |
|---|---|
| 177Lu-PSMA-I&T | Phase 3 |
| 18F-DCFPyL | Phase 2 |
| 225Ac-J591 | Phase 1 |
| 5-FU | Phase 4 |
| Abiraterone | Phase 4 |
| Abiraterone acetate | Phase 4 |
| Abiraterone acetate 250 mg or 500 mg tablets | Phase 4 |
| Abiraterone Oral Tablet | Phase 4 |
| ADT + Apalutamide | Phase 4 |
| ADT + Enzalutamide | Phase 4 |
Showing 10 of 176 candidates. Sign up for full pipeline.
Upcoming Catalysts (18)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$7.5M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 400,000 | $2.7M |
| vanguard capital management llc | 313,214 | $2.1M |
| susquehanna international group, llp | 89,400 | $606K |
| blackrock, inc. | 84,331 | $572K |
| two sigma investments, lp | 49,511 | $336K |
| geode capital management, llc | 45,998 | $312K |
| renaissance technologies llc | 27,481 | $186K |
| vanguard fiduciary trust co | 23,942 | $162K |
| birchview capital, lp | 22,566 | $153K |
| state street corp | 20,284 | $138K |
Showing top 10 of 31 institutional holders of KYNTRA BIO INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in KYNTRA BIO INC.'s pipeline?
KYNTRA BIO INC. (KYNB) has 176 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KYNTRA BIO INC.'s lead drug candidate?
KYNTRA BIO INC.'s most advanced tracked candidate is 177Lu-PSMA-I&T (Phase 3) for Metastasis From Malignant Tumor of Prostate.
What is KYNTRA BIO INC.'s next catalyst?
KYNTRA BIO INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or" — expected June 30, 2026.
What is KYNTRA BIO INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KYNTRA BIO INC. has approximately 19.2 months of cash runway.
What is KYNTRA BIO INC.'s market capitalization?
KYNTRA BIO INC.'s market capitalization is approximately $28.3M.
Get the full picture on KYNTRA BIO INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.